Significant improvement of a nevus spilus-type congenital melanocytic nevus with oral selumetinib

2Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Giant congenital melanocytic nevi (GCMN) can be cosmetically significant and can lead to melanoma. There is no standard pharmacologic treatment for GCMN. We present the case of an 8-year-old female with kaposiform lymphangiomatosis caused by an NRAS mutation whose nevus spilus-type GCMN improved on oral selumetinib.

Cite

CITATION STYLE

APA

Berna, R., Hasbun, T., Adams, D., Moon, A. T., & Treat, J. R. (2024, September 1). Significant improvement of a nevus spilus-type congenital melanocytic nevus with oral selumetinib. Pediatric Dermatology. John Wiley and Sons Inc. https://doi.org/10.1111/pde.15666

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free